Treatment of bisphosphonate-related osteonecrosis of the jaw using platelet-rich fibrin

1Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND Bisphosphonates are commonly prescribed antiresorptive agents for the management of patients with osteoporosis, Paget's disease, multiple myeloma, and metastatic tumors. Platelet-rich fibrin (PRF) is a second generation platelet concentrate, and has the ability of regulating the inflammation and stimulation of chemotactic agents. The aim of this report is to present the treatment of Stage-3 bisphosphonate-related osteonecrosis of the jaw (BRONJ) by PRF. CLINICAL PRESENTATION A 77-year-old male patient with Stage-3 BRONJ was treated with minimal surgical operations and PRF membrane. The patient was followed up for 18 months, and there was no recurrence or exposure. CONCLUSION PRF may promote the healing of both bone and soft tissues even in Stage-3 patients. This technique is an alternative treatment modality for the closure of bone exposure and tissue healing in BRONJ patients.

Cite

CITATION STYLE

APA

Gönen, Z. B., & Yılmaz Asan, C. (2017). Treatment of bisphosphonate-related osteonecrosis of the jaw using platelet-rich fibrin. Cranio - Journal of Craniomandibular Practice, 35(5), 332–336. https://doi.org/10.1080/08869634.2016.1203093

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free